OR02-4 YAP1 Overexpression Associates With Worse Prognosis In Patients With Adrenal Tumors And YAP1 Inhibition By Verteporfin Reduces Tumorigenicity And Reverses Epithelial-mesenchymal Transition In Adrenocortical Tumor Cells

Background: There is no effective adjuvant therapy for patients with advanced adrenocortical tumors (ACT). Abnormal YAP1, a HIPPO pathway effector, is involved in some types of cancers. Recently, we showed association of the overexpression of YAP1 in pediatric ACT (pACT) with worse prognosis, but it...

Descripción completa

Detalles Bibliográficos
Autores principales: Bellido More, Candy, Bueno, Ana, De Castro, Margaret, Rauber Antonini, Sonir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Adrenal
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6554785/
http://dx.doi.org/10.1210/js.2019-OR02-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6554785/
http://dx.doi.org/10.1210/js.2019-OR02-4

Ejemplares similares